Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 6, 2006 - Issue 7
Submit an article Journal homepage
198
Views
39
CrossRef citations to date
0
Altmetric
Drug Profile

Bupropion for the treatment of nicotine withdrawal and craving

Marc E Mooney University of Minnesota, Department of Psychiatry, Tobacco Use Research Center 2701 University Avenue, Suite 201, Minneapolis, MN 55414, USA. [email protected]
&
Mehmet Sofuoglu Yale University, Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Avenue, Bldg, 36/116A4, West Haven, CT 06516, USA. [email protected]
Pages 965-981 | Published online: 10 Jan 2014

References

  • Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int. J. Cancer116(6), 963–971 (2005).
  • Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation112(4), 489–497 (2005).
  • Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet362(9387), 847–852 (2003).
  • Centers for Disease Control. Annual smoking-attributable mortality, years of potential life lost, and productivity losses. USA, 1997–2001. MMWR Morb. Mortal. Wkly Rep.54(25), 625–658 (2005).
  • Fiore MC, Bailey WC, Cohen SJ et al. Treating tobacco use and dependence clinical practice guideline. AHRQ Publication No. 00–0032, Department of Health and Human Services Washington DC, USA (2000).
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV 4th Edition. American Psychiatric Association, Washington, DC, USA (1994).
  • Piasecki TM, Fiore MC, McCarthy DE, Baker TB. Have we lost our way? The need for dynamic formulations of smoking relapse proneness. Addiction97(9), 1093–1108 (2002).
  • Ockene JK, Emmons KM, Mermelstein RJ et al. Relapse and maintenance issues for smoking cessation. Health Psychol.19(1 Suppl.), 17–31 (2000).
  • Malin DH. Nicotine dependence: studies with a laboratory model. Pharmacol. Biochem. Behav.70(4), 551–559 (2001).
  • Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav.70(4), 531–549 (2001).
  • Hughes JR, Gust SW, Skoog, K, Keenan RM, Fenwick JW. Symptoms of tobacco withdrawal. A replication and extension. Arch. Gen. Psychiatry48(1), 52–59 (1991).
  • Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry43(3), 289–294 (1986).
  • Epping-Jordan MP, Watkins SS, Koob GF, Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature393(6680), 76–79 (1998).
  • Suzuki T, Ise Y, Tsuda M, Maeda J, Misawa M. Mecamylamine-precipitated nicotine-withdrawal aversion in rats. Eur. J. Pharmacol.314(3), 281–284 (1996).
  • Hughes JR, Gust SW, Pechacek TF. Prevalence of tobacco dependence and withdrawal. Am. J. Psychiatry144(2), 205–208 (1987).
  • Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp. Clin. Psychopharmacol.5(2), 137–142 (1997).
  • West R, Schneider N. Craving for cigarettes. Br. J. Addict.82(4), 407–115 (1987).
  • Gritz ER, Carr CR, Marcus AC. The tobacco withdrawal syndrome in unaided quitters. Br. J. Addict.86(1), 57–69 (1991).
  • Hatsukami DK, Hughes JR, Pickens RW, Svikis D. Tobacco withdrawal symptoms: an experimental analysis. Psychopharmacology (Berl.)84(2), 231–236 (1984).
  • West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol. Med.19(4), 981–985 (1989).
  • Piasecki TM, Fiore MC, Baker TB. Profiles in discouragement: two studies of variability in the time course of smoking withdrawal symptoms. J. Abnorm. Psychol.107(2), 238–251 (1998).
  • Piasecki TM, Niaura R, Shadel WG et al. Smoking withdrawal dynamics in unaided quitters. J. Abnorm. Psychol.109(1), 74–86 (2000).
  • Hughes JR, Higgins ST, Bickel WK. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction89(11), 1461–1470 (1994).
  • Maude-Griffin P, Tiffany ST. Production of smoking urges through imagery: the impact of affect and smoking abstinence. Exp. Clin. Psychopharmacol.4(2), 198–208 (1996).
  • Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br. J. Addict.86(11), 1467–1476 (1991).
  • Carter BL, Tiffany ST. The cue-availability paradigm: the effects of cigarette availability on cue reactivity in smokers. Exp. Clin. Psychopharmacol.9(2), 183–190 (2001).
  • Hughes JR, Higgins ST, Hatsukami D. Effects of abstinence from tobacco: a critical review. In: Research Advance in Alcohol and Drug Problems. Kozlowski H (Ed.), Plenum Press, NY, USA, 317–398 (1990).
  • Patten CA, Martin JE. Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Ann. Behav. Med.18(3), 190–200 (1996).
  • Kenford SL, Smith SS, Wetter DW et al. Predicting relapse back to smoking: contrasting affective and physical models of dependence. J. Consult. Clin. Psychol.70(1), 216–227 (2002).
  • Brandon TH, Tiffany ST, Obremski KM, Baker TB. Postcessation cigarette use: the process of relapse. Addict. Behav.15(2), 105–114 (1990).
  • Koob GF, Stinus L, Le Moal M, Bloom FE. Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci. Biobehav. Rev.13(2–3), 135–140 (1989).
  • O’Connell KA, Shiffman S. Negative affect smoking and smoking relapse. J. Subst. Abuse1(1), 25–33 (1988).
  • Payne TJ, Smith PO, Sturges LV, Holleran SA. Reactivity to smoking cues: mediating roles of nicotine dependence and duration of deprivation. Addict. Behav.21(2), 139–154 (1996).
  • Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res.2(1), 19–37 (2000).
  • Zinser MC, Baker TB, Sherman JE, Cannon DS. Relation between self-reported affect and drug urges and cravings in continuing and withdrawing smokers. J. Abnorm. Psychol.101(4), 617–629 (1992).
  • Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev.3, (2004).
  • Hughes JR. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J. Consult. Clin. Psychol.61(5), 751–760 (1993).
  • George TP, O’Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci.25(1), 42–48 (2004).
  • Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int. J. Clin. Pract.60(5), 571–576 (2006).
  • Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev.4, CD000031 (2004).
  • Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict. Biol.10(3), 219–231 (2005).
  • Feighner JP, Meredith CH, Stern WC, Hendrickson G, Miller LL. A double-blind study of bupropion and placebo in depression. Am. J. Psychiatry141(4), 525–529 (1984).
  • Pitts WM, Fann WE, Halaris AE et al. Bupropion in depression: a tri-center placebo-controlled study. J. Clin. Psychiatry44(5 Pt 2), 95–100 (1983).
  • Ferry LH, Burchette RJ. Bupropion for smoking cessation in non depressed smokers. J. Addict. Dis.13(4), 249–249 (1994).
  • Hurt RD, Sachs DP, Glover ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med.337(17), 1195–1202 (1997).
  • Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med.340(9), 685–691 (1999).
  • George TP, Vessicchio JC, Termine A et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol. Psychiatry52(1), 53–61 (2002).
  • Hayford KE, Patten CA, Rummans TA et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br. J. Psychiatry174, 173–178 (1999).
  • Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J. Clin. Psychopharmacol.21(1), 94–98 (2001).
  • Tashkin D, Kanner R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet357(9268), 1571–1575 (2001).
  • Tonstad S, Farsang C, Klaene G et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur. Heart J.24(10), 946–955 (2003).
  • Hays JT, Hurt RD, Rigotti NA et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann. Intern. Med.135(6), 423–433 (2001).
  • Cousins MS, Stamat HM, de Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl.)157(3), 243–253 (2001).
  • Swan GE, McAfee T, Curry SJ et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch. Intern. Med.163(19), 2337–2344 (2003).
  • Bondarev ML, Bondareva TS, Young R, Glennon RA. Behavioral and biochemical investigations of bupropion metabolites. Eur. J. Pharmacol.474(1), 85–93 (2003).
  • Physicians’ Desk Reference. Montvale Thompson PDR, NJ, USA (2006).
  • Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport13(9), 1097–1106 (2002).
  • Wise RA. The role of reward pathways in the development of drug dependence. Pharmacol. Ther.35(1–2), 227–263 (1987).
  • Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry56(9), 395–401 (1995).
  • Learned-Coughlin SM, Bergstrom M, Savitcheva I et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry54(8), 800–805 (2003).
  • Meyer JH, Goulding VS, Wilson AA et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl.)163(1), 102–105 (2002).
  • Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology168(3), 347–358 (2003).
  • Hutchison KE, Rutter MC, Niaura R et al. Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology. (Berl.)175(4), 407–413 (2004).
  • Brody AL, Mandelkern MA, Lee G et al. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res.130(3), 269–281 (2004).
  • Aston-Jones G, Harris GC. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology47(Suppl. 1), 167–179 (2004).
  • Delfs JM, Zhu Y, Druhan JP, Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature403(6768), 430–434 (2000).
  • Trauth JA, Seidler FJ, Ali SF, Slotkin TA. Adolescent nicotine exposure produces immediate and long-term changes in CNS noradrenergic and dopaminergic function. Brain Res.892(2), 269–280 (2001).
  • Glassman AH, Jackson WK, Walsh BT, Roose SP, Rosenfeld B. Cigarette craving, smoking withdrawal, and clonidine. Science226(4676), 864–866 (1984).
  • Ornish SA, Zisook S, McAdams LA. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial. Arch. Intern. Med.148(9), 2027–2031 (1988).
  • Cooper BR, Wang CM, Cox RF et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology11(2), 133–141 (1994).
  • Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl.)155(1), 52–57 (2001).
  • Golden RN, De Vane CL, Laizure SC et al. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch. Gen. Psychiatry45(2), 145–149 (1988).
  • Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther.295(1), 321–327 (2000).
  • Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther.288(1), 88–92 (1999).
  • Damaj MI, Carroll FI, Eaton JB et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol.66(3), 675–682 (2004).
  • Coe JW, Brooks PR, Vetelino MG et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem.48(10), 3474–3477 (2005).
  • Rose JE, Behm FM, Westman EC et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther.56(1), 86–99 (1994).
  • Johnston AJ, Ascher J, Leadbetter R et al. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs62(Suppl. 2), 11–24 (2002).
  • Daviss WB, Perel JM, Rudolph GR et al. Steady-state pharmacokinetics of bupropion SR in juvenile patients. J. Am. Acad. Child Adolesc. Psychiatry44(4), 349–357 (2005).
  • Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: a review. J. Clin. Psychiatry44(5 Pt 2), 82–84 (1983).
  • Wiley JL, Lavecchia KL, Martin BR, Damaj MI. Nicotine-like discriminative stimulus effects of bupropion in rats. Exp. Clin. Psychopharmacol.10(2), 129–35 (2002).
  • Young R, Glennon RA. Nicotine and bupropion share a similar discriminative stimulus effect. Eur. J. Pharmacol.443(1–3), 113–118 (2002).
  • Bruijnzeel AW, Markou A. Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse50(1), 20–28 (2003).
  • Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl.)169(1), 1–9 (2003).
  • Shoaib, M, Sidhpura N, Shafait S. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl.)165(4), 405–412 (2003).
  • Malin DH, Lake JR, Smith TD et al. Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl.)1–10 (2005).
  • Hall SM, Munoz RF, Reus VI, Sees KL. Nicotine, negative affect, and depression. J. Consult. Clin Psychol.61(5), 761–767 (1993).
  • Huston-Lyons D, Kornetsky C. Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol. Biochem. Behav.41(4), 755–759 (1992).
  • Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol. Rev.111(1), 33–51 (2004).
  • Shiffman S, West R, Gilbert D. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob. Res.6(4), 599–614 (2004).
  • Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl.)184(3–4), 274–285 (2006).
  • Lu L, Grimm JW, Hope BT, Shaham Y. Incubation of cocaine craving after withdrawal: a review of preclinical data. Neuropharmacology47(Suppl. 1), 214–226 (2004).
  • Schroeder DH. Metabolism and kinetics of bupropion. J. Clin. Psychiatry44(5 Pt 2), 79–81 (1983).
  • Rukstalis M, Jepson C, Strasser A et al. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl.)180(1), 41–48 (2005).
  • Shiffman S, Johnston JA, Khayrallah M et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl.)148(1), 33–40 (2000).
  • Teneggi V, Tiffany ST, Squassante L et al. Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology (Berl.)183(1), 1–12 (2005).
  • West R, Hajek P, Belcher M. Time course of cigarette withdrawal symptoms while using nicotine gum. Psychopharmacology (Berl.)99(1), 143–145 (1989).
  • Brauer LH, Behm FM, Westman EC, Patel P, Rose JE. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Berl.)143(4), 339–346 (1999).
  • Epstein AM, King AC. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol. Biochem. Behav.77(1), 29–37 (2004).
  • King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol. Biochem. Behav.66(3), 563–572 (2000).
  • Schneider NG, Jarvik ME. Time course of smoking withdrawal symptoms as a function of nicotine replacement. Psychopharmacology (Berl.)82(1–2), 143–144 (1984).
  • Shiffman SM, Jarvik ME. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl.)50(1), 35–39 (1976).
  • Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob. Res.3(1), 7–16 (2001).
  • Shiffman S. Variation in bupropion findings is not due to differences in measurement: comment on Teneggi. Psychopharmacology (Berl.)185(3), 400–401 (2006).
  • Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl.)184(3–4), 628–636 (2006).
  • Conklin CA. Environments as cues to smoke: implications for human extinction-based research and treatment. Exp. Clin. Psychopharmacol.14(1), 12–19 (2006).
  • Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol.51(6), 1173–1182 (1986).
  • Lerman C, Niaura R, Collins BN et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol . Addict. Behav.18(4), 362–366 (2004).
  • Lerman C, Roth D, Kaufmann V et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend.67(2), 219–223 (2002).
  • McCarthy DE, Bolt DM, Baker TB. The importance of how: a call for mechanistic research in tobacco dependence treatment studies. In: Psychological Clinical Science: Recent Advances In Theory and Practice. Integrative perspectives in honor of RM McFall. Baker TB, Bootzin RI, Treat T (Eds), Lawrence Erlbaum Associates, NY, USA (2006) (In Press).
  • Piper ME, Federman EB, Bolt DM et al. Mediators of bupropion treatment effects. In: Proceedings of the 12th Society for Research on Nicotine and Tobacco. Orlando, USA (2006).
  • Hurt RD, Krook JE, Croghan IT et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J. Clin. Oncol.21(5), 914–920 (2003).
  • Killen JD, Robinson TN, Ammerman S et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J. Consult. Clin. Psychol.72(4), 729–735 (2004).
  • Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. Arch. Intern. Med.164(16), 1797–1803 (2004).
  • Glover ED, Glover PN, Sullivan CR, Cerullo CL, Hobbs G. A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation. Am. J. Health Behav.26(5), 386–393 (2002).
  • Hatsukami DK, Rennard S, Patel MK et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Am. J. Med.116(3), 151–157 (2004).
  • Gonzales DH, Nides MA, Ferry LH et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin. Pharmacol. Ther.69(6), 438–44 (2001).
  • Hall SM, Humfleet GL, Reus VI et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry59(10), 930–936 (2002).
  • Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch. Intern. Med.165(19), 2286–2292 (2005).
  • Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am. J. Psychiatry158(4), 635–637 (2001).
  • Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA288(4), 468–474 (2002).
  • Tonnesen P, Tonstad S, Hjalmarson A et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J. Intern. Med.254(2), 184–192 (2003).
  • Perkins KA, Levine MD, Marcus MD, Shiffman S. Addressing women's concerns about weight gain due to smoking cessation. J. Subst . Abuse Treat14(2), 173–182 (1997).
  • Klesges RC, Meyers AW, Klesges LM, La Vasque ME. Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature. Psychol. Bull.106(2), 204–230 (1989).
  • Evins AE, Mays VK, Rigotti NA et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob. Res.3(4), 397–403 (2001).
  • Dalsgarð OJ, Hansen NC, Soes-Petersen U et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob. Res.6(1), 55–61 (2004).
  • Durcan MJ, Deener G, White J et al. The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin. Ther.24(4), 540–551 (2002).
  • Tsoh JY, Humfleet GL, Munoz RF et al. Development of major depression after treatment for smoking cessation. Am. J. Psychiatry157(3), 368–374 (2000).
  • Shiffman S, Engberg JB, Paty JA et al. A day at a time: predicting smoking lapse from daily urge. J. Abnorm. Psychol.106(1), 104–116 (1997).
  • Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs62(Suppl. 2), 45–52 (2002).
  • Fatemi SH, Stary JM, Hatsukami DK, Murphy SE. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr. Res.76(2–3), 353–356 (2005).
  • Settle EC Jr. Bupropion sustained release: side-effect profile. J. Clin. Psychiatry59(Suppl. 4), 32–36 (1998).
  • Lerman C, Jepson C, Wileyto EP et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology31(1), 231–242 (2006).
  • Lerman C, Shields PG, Wileyto EP et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol.22(5), 541–548 (2003).
  • Lerman C, Shields PG, Wileyto EP et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics12(8), 627–634 (2002).

Website

  • Conference abstracts of the Society for Research on Nicotine and Tobacco, www.srnt.org

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.